Acute and chronic inflammatory biliary tract disease has ever since been in the vanguard of gastrointestinal medicine at the interface between surgical and medical care. Likewise, biliary system disorders demand the cooperation between high-volume specialized and community-based patient care, ranging from standard cholecystectomy over personalized assessment of bile duct strictures to liver transplantation for chronic cholestatic liver diseases. In this sense, inflammatory biliary diseases represent a timeless but vital topic forming the overarching theme of the current edition of Viszeralmedizin to which we as Guest Editors warmly welcome you.
In this issue old acquaintances will be revisited and new ones be met -such as the emerging topic of the biliary mucosal barrier and the microbiome. This fascinating, novel topic, though still in its infancy, will be introduced by Verdier, Luedde and Sellge [1] from Aachen. Contrary to the paradigm of a sterile biliary milieu under healthy conditions, new data suggest a complex commensal colonization as well as specialized defence and tolerance mechanisms within the biliary system. The impact of this biliary mucosal barrier on chronic hepatobiliary diseases has to be substantiated further in the future. Schuld and Glanemann [2] , Homburg, present a stateof-the-art update on the management of acute cholecystitis, representing one of the most common emergencies in visceral medicine. In contrast to the die-hards of hard rock still touring around the world, the recent ACDC trial has set a general standard of care with acute cholecystectomy being performed within the first 24 h after hospitalization that has been embraced and specified by interdisciplinary guidelines. Zimmer and Lammert [3] from Homburg present an update on the mostly endoscopic management of acute bacterial cholangitis and put adequate diagnosis including imaging microbiology and timing as well as modalities of biliary drainage into perspective.
Primary sclerosing cholangitis (PSC) as a chronic fibro-obliterative disease of the larger bile ducts is the remaining 'black box' of hepatology. For this highly cancer-prone disease of unknown aetiology, there are neither sufficient diagnostic tools nor treatment options available. Reasonable suggestions for patient care by experts in
